Significant enhancement in 2-year EFS with axi-cell versus rescue chemoimmunotherapy + ASCT in refractory-relapsed DLBC-NHL. Toxicities, costs, operational aspects of CAR T-cell remain significant barriers in community oncology. Hopefully, enhanced products, technologies will allow broader utilization of CAR T-cell in the future.
Timely update. MRD monitoring post-surgery will likely change this paradigm in the next few years. In the meantime, this is a good summary and in-depth discussion. Follow-up is necessary to understand impact on overall survival.
Negative study that documents failure of accretive benefit of TDM1/pertuzumab over trastuzumab/pertuzumab. Exploration of other pathways or target/payload will be necessary for clinical improvement/risk reduction of recurrence.
Early study but more supportive data for bispecific antibodies in this setting. Community oncology will soon have an array of options and understanding/managing toxicities will be important for this class of drugs.
MRD status in MM has unquestionable prognostic informational value, however many questions remain as how to address positive / negative MRD results. Should we de-escalate or stop Rx? When? Can we escalate Rx if + MRD? Which regimen, how long? It will be another few years till objective data are available. I do see value in at least having identification of clonality established upfront for tracking.
Is there a better CAR-T cell product in this setting? Are negative results of this trial due to different patient population or imbalance in 2 arms of the study? Certainly disappointing result, but further studies may define they most adequate group of patients to benefit from therapy.
Given relatively low-toxicities of capecitabine, it is reasonable to consider it especially in a population with fewer comorbidities and preserved performance-status. More data pertaining OS differences will be welcome. Study is relatively small but not unusual for this diagnosis.
Interesting paper which gives support to early and aggressive screening of non-BRCA mutations. Helpful data to assist with patient education and obtain approval of preventive screening, though modeling analysis is the main strength of the article.
With the rapid adoption of technology, digital solutions and new modalities in the wake of COVID-19, cancer patients and extended care teams have a plethora of resources geared towards improving access, reducing financial toxicity and easing the burden of navigation. And yet, many remain lost within the labyrinth of information overload. This article highlights the increasing need to go beyond HUB services and a convener approach, and instead look to root causes with the patient at the center.
This is an important progress for patients with KRASG12C mutation. Median PFS of 11 months is very encouraging for a previously “undruggable” molecular signature.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
